—
C+
C+ The full Closelook — membership. Open the C+ overview

Pfizer Inc (PFE) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Pfizer Inc

PFE in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Pfizer discovers, develops, manufactures and sells biopharmaceutical products worldwide, organised into three segments: Biopharma, PC1 and Pfizer Ignite. Its brands cover internal medicine such as Eliquis and Nurtec, vaccines such as Prevnar and Abrysvo, inflammation and immunology treatments such as Xeljanz and Enbrel, rare disease medicines such as Vyndaqel, oncology therapies such as Ibrance and Xtandi, and biosimilars and sterile injectables. It is headquartered in New York and has traded publicly since 1942.
Where it sits in the stack
Pfizer holds no seat in Rubin, the diary's AI build-out index, and sits outside that stack. In our wider universe it belongs to the healthcare sleeve, under drug manufacturing, alongside other large diversified pharmaceutical companies.
Who it is priced against
The diary records no formal peer group for Pfizer; the comparison the market draws is with other large diversified drug makers such as Merck.
Why Closelook tracks it
Pfizer carries a seat in the S&P 500 but no Closelook score. The diary's Daily Pulse has grouped it among the defensive names its pattern scanner watches for support, most recently tagged with a caution rather than stress regime.
What the diary watches
Whether Pfizer keeps printing the caution regime the pattern scanner has assigned it, or shifts alongside the other defensive names it has been grouped with when broader risk sentiment moves.

Pfizer Inc (PFE) trades on US exchanges.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: PFE news on the tape · index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for PFE, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 3 macro readings: Money Temperature, Factor regime, Sovereign pressure

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 55/100 · S&P 500 fund at 58, above its 50- and 200-day averagesEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-17
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 94th percentile of the window, +2.7% over 20 sessions. Factor regime → 2026-09-17
  • Sovereign pressure Index 0.00 · down 0.41 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-17

FAQ · from the current data · as of 2026-09-18

Quick answers

What is Pfizer Inc (PFE)?

Pfizer Inc trades as PFE on the US exchange (US) in the Closelook research universe, as of the registry build of 2026-09-18.

Is PFE in a Closelook index?

Not currently — Pfizer Inc is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-18.

Where does PFE trade against its moving averages?

Uptrend stack intact: Trades +4.4% vs the 50-day and +5.7% vs the 200-day average, 5.4% below the 52-week high and +21.3% off the 52-week low; a golden cross printed 6 sessions ago. Computed from daily closes. As of 2026-09-17 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Pfizer Inc do?

Pfizer discovers, develops, manufactures and sells biopharmaceutical products worldwide, organised into three segments: Biopharma, PC1 and Pfizer Ignite. Its brands cover internal medicine such as Eliquis and Nurtec, vaccines such as Prevnar and Abrysvo, inflammation and immunology treatments such as Xeljanz and Enbrel, rare disease medicines such as Vyndaqel, oncology therapies such as Ibrance and Xtandi, and biosimilars and sterile injectables. It is headquartered in New York and has traded publicly since 1942. The diary records no formal peer group for Pfizer; the comparison the market draws is with other large diversified drug makers such as Merck.

Where does Pfizer Inc sit in the AI build-out?

Pfizer holds no seat in Rubin, the diary's AI build-out index, and sits outside that stack. In our wider universe it belongs to the healthcare sleeve, under drug manufacturing, alongside other large diversified pharmaceutical companies. Pfizer carries a seat in the S&P 500 but no Closelook score. The diary's Daily Pulse has grouped it among the defensive names its pattern scanner watches for support, most recently tagged with a caution rather than stress regime.

Where has Closelook written about Pfizer Inc?

Pfizer Inc appears in 7 Closelook pieces, most recently Daily Pulse: Rubin surges as vol complex splits and Europe extends gains (2026-05-22); Daily Pulse: Layer-1 chips surge as Europe and US futures fade (2026-05-21); Daily Pulse: Narrow tape: Rubin leads as broad market softens across asset classes (2026-05-20). What Closelook said most recently: The reading sits just above the neutral midpoint, consistent with a market that has bounced but not yet committed to a sustained risk-on regime. §11 — Pattern Scanner Active 28 signals · PFE 36 🟡 support-confluence · MCD 36 🟡… (Daily Pulse, 2026-05-21). The "Mentioned on Closelook" block on this page lists the long reads, the reference entries and the dailies that name it.

What does this page show?

A live price chart with SMA overlays and drawing tools for PFE, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Mentioned on Closelook 7 pieces · newest: Daily Pulse, “Rubin surges as vol complex splits and Europe extends gains” (2026-05-22)

Mentioned on Closelook

Where PFE appears in the diary — 7 pieces, newest first. Every link is our own writing.

Dailies

Related in the Closelook universe